A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Overview
The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The main questions the study aims to answer are:
* What is an appropriate dose of CHM-029?
* What side effects may occur with CHM-029?
* How does the body process CHM-029?
Researchers will evaluate increasing dose levels of CHM-029 to better understand its safety and how the body responds to treatment.
Participants will visit the study clinic regularly for safety assessments, blood tests, electrocardiograms (ECGs), and bone marrow evaluations to monitor their health and response to treatment.
Detailed Description
CHM-029-01 is a Phase 1/2, first-in-human, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antileukemic activity of orally administered CHM-029 in adults with relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation, KMT2A rearrangement, or NUP98 rearrangement.
Who Can Participate
Inclusion Criteria
18 years old and above
Relapsed or refractory (R/R) acute myeloid leukemia (AML) and has had treatment with any available standard therapies
Positive for NPM1 mutation, or KMT2A or NUP98 rearrangements
Exclusion Criteria
White blood cell (WBC) count higher than 25,000 u/L that cannot be maintained below threshold with hydroxyurea treatment
Extramedullary only AML
Has current complications related to hematopoietic stem cell transplant (HSCT)
Other cancers that require treatment
Active Hepatitis or HIV infection
Moderate hepatic or renal impairment
Acute promyelocytic leukemia
Baseline prolongation of QT/QTc interval (≥ 470 ms) or additional risk factors for Torsades de Pointes (TdP)
Congestive heart failure NYHA Class 3 or 4
Central nervous system involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Disclaimer
This summary is based on publicly available information from clinicaltrials.gov and is intended to help patients discuss possible trial options with their oncology care team. ClinicalTrials.gov and related public listings do not independently review or approve the safety and scientific merit of every study.
Participation decisions can be made only after review by the study team and your treating clinician.